查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370910

C反应蛋白检测市场－2018-2028年全球产业规模、份额、趋势、机会与预测，依检测类型、检测范围、疾病领域、最终用途产业、地区、竞争细分

C-reactive Protein Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Assay Type, By Detection Range, By Disease Area, By End-Use Industry, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球 C 反应蛋白检测市场价值达到 16.0101 亿美元，并预计在预测期内强劲增长，预计到 2028 年复合年增长率 (CAGR) 为 2.16%，预计将达到 1835.28 美元到2028 年将达到100万。C 反应蛋白测试是一项实验室检查，可评估血液中C 反应蛋白的水平。这种特殊的蛋白质是由肝臟响应身体发炎而合成的。它是人体对感染、损​​伤或其他发炎刺激的先天免疫反应的一个组成部分。通常，CRP 检测涉及血液样本，结果以每公升血液中 CRP 毫克数 (mg/L) 的形式报告。正常的 CRP 水平通常较低，而升高的水平可能意味着持续的发炎或感染。值得注意的是，吸烟、肥胖和某些药物等因素也会影响 CRP 水平。 CRP 测试通常在各种医学环境中用作发炎标记。医疗保健专业人员经常要求进行 CRP 检测，以帮助诊断和监测一系列疾病，包括感染、自体免疫疾病、心血管疾病、创伤或手术以及治疗监测。

主要市场驱动因素

  • 1.发炎和传染病的发生率不断上升：发炎和传染病的盛行率不断上升，大大促进了全球C反应蛋白（CRP）检测市场的扩大。这些疾病通常会引发免疫反应，导致血液中 CRP 水平升高。随着这些疾病发生率的上升，医疗保健提供者越来越需要可靠的诊断工具来检测和监测发炎。 CRP 检测提供了一种方便有效的评估发炎程度的方法，有助于各种病症的诊断和管理。及时检测发炎对于有效的疾病管理和併发症预防至关重要。 CRP 测试可以及早发现炎症，使医疗保健专业人员能够在病情恶化之前进行干预。这符合关注预防性医疗保健和早期疾病检测的更广泛趋势。许多慢性疾病，例如类风湿性关节炎、发炎性肠道疾病和某些自体免疫疾病，都涉及持续的发炎。 CRP 测试可帮助临床医生监测发炎的严重程度并相应调整治疗计划。随着这些慢性病的盛行率增加，对 CRP 检测作为监测工具的需求也在增加。发炎是心血管疾病 (CVD) 的公认危险因素，包括心臟病发作和中风。 CRP 水平升高与 CVD 风险增加有关。医疗保健提供者将 CRP 测试作为 CVD 整体风险评估的一部分，这可能会影响治疗决策和生活方式建议。 CRP 水平会因细菌和病毒感染而升高。监测 CRP 水平有助于追踪感染进展、评估抗菌疗法的有效性以及确定患者何时康復。发炎和传染病的日益普及促使人们对发炎在各种健康状况中的作用进行了广泛的研究。这项研究深入了解了 CRP 水平与疾病结果之间的关係，进一步强调了 CRP 检测在临床实践中的重要性。
市场概况
预测期 2024-2028
2022 年市场规模 160101万美元
2028 年市场规模 18.3528亿美元
2023-2028 年复合年增长率 2.16%
成长最快的细分市场 免疫比浊分析
最大的市场 北美洲
  • 2.预防保健意识的提高：预防保健意识的提高极大影响了全球C反应蛋白（CRP）检测市场的成长。预防性医疗保健的重点是在早期阶段，甚至在症状变得明显之前，识别健康问题。在这种情况下，CRP 检测是一种有价值的工具，可检测临床上可能尚不明显的低度发炎。透过 CRP 检测及早发现发炎可以及时干预和管理，有可能预防潜在疾病的进展。预防性医疗保健通常涉及评估个人患某些疾病的风险。 CRP 测试可以提供有关个人发炎程度的信息，有助于风险分层。 CRP 水平升高与心血管疾病等疾病的风险增加有关，因此 CRP 测试成为风险评估方案的重要组成部分。预防保健意识促进了针对个人特定风险因素和健康需求量身定制个人化健康计划的概念。 CRP 测试增加了一个客观的生物标记来指导这些个人化计划，帮助医疗保健提供者设计干预措施和生活方式改变，以解决发炎相关风险。预防保健通常强调改变生活方式以促进更好的健康结果。 CRP 测试结果可以作为一个有形的标记，激励个人做出更健康的选择，例如改善饮食、增加体力活动和戒烟。 CRP 检测的可用性支援旨在帮助个人掌控自己健康的教育工作。公共卫生措施和筛检计画是预防性医疗保健工作的一部分。 CRP 测试可以整合到这些计划中，以识别有发炎和相关疾病风险的个体。这种积极主动的方法可以实现早期干预，减轻慢性病对医疗保健系统的负担。
  • 3.老年人口和相关慢性病的增加：老年人口的增加和相关慢性病的盛行率在推动全球C反应蛋白（CRP）检测市场的成长方面发挥着重要作用。老化与免疫系统的变化有关，使老年人更容易受到发炎的影响。慢性低度发炎（称为发炎）在老年人中很常见，并导致各种与年龄相关的慢性疾病的发展。 CRP 测试是评估和监测这种慢性发炎的重要工具，可深入了解疾病风险和进展。老年人更容易罹患心血管疾病、糖尿病、骨关节炎和某些癌症等慢性疾病。 CRP 测试可帮助医疗保健提供者评估这些疾病的发炎成分，从而帮助诊断、管理和监测。老年人罹患心血管疾病的风险增加，而发炎是其发病机制的关键因素。 CRP 检测用于评估心血管风险并指导治疗决策，特别是在老年族群中，预防措施至关重要。老年人常同时患有多种慢性病。 CRP 测试可深入了解整体发炎状态，帮助医疗保健提供者更有效地管理多种疾病并做出明智的治疗选择。由于免疫系统与年龄相关的变化，老年人更容易受到感染。 CRP 水平会因感染而升高，有助于评估和监测传染病，这可能对老年人造成更严重的后果。老年族群的预防保健强调早期发现和干预，以防止疾病进展并提高生活品质。 CRP 测试透过在早期阶段检测炎症，有助于及时干预和个人化治疗计划，有助于这种方法。老年护理设施和长期照护机构通常为具有复杂健康需求的个人提供服务。 CRP 检测是这些环境中监测居民健康、识别潜在感染和管理慢性病的宝贵工具。

主要市场挑战

  • 1. CRP升高的非特异性：C反应蛋白（CRP）水平升高的非特异性对全球CRP检测市场构成挑战，主要是因为它可能导致诊断和治疗决策的不确定性。 CRP 水平升高表明存在炎症，但它们并不能提供有关炎症根本原因的具体资讯。这种特异性的缺乏可能会导致诊断混乱，因为医疗保健提供者可能需要进行额外的测试来找出导致 CRP 升高的确切情况。因此，可能会延迟诊断实际的潜在疾病。 CRP 升高的非特异性性质可能会导致过度或不恰当地进行 CRP 检测，从而导致不必要的医疗成本和资源利用。如果存在发炎但没有临床意义，医疗保健提供者可能会要求 CRP 检测，这可能会导致过度诊断和过度使用医疗服务。
  • 2.不同的参考范围：不同的实验室和医疗机构可能使用不同的参考范围

用于定义正常、升高和高 CRP 水平。这种不一致可能会导致医疗保健提供者和患者在解释 CRP 测试结果时产生混淆。在一种情况下被认为正常的值在另一种情况下可能被归类为升高，从而影响临床决策。不同的参考范围可能会不确定给定的 CRP 水平是否在正常范围内或是否指示发炎。这种模糊性可能会对准确诊断发炎状况造成挑战，可能会延迟适当的治疗和管理。建立 CRP 水平标准化参考范围的努力有助于确保不同环境和实验室之间的解释一致。专业医疗组织可以根据临床证据和共识提供解释 CRP 检测结果和定义参考范围的指南和建议。

  • 3.外部因素的影响：外部因素对C反应蛋白（CRP）水平的影响可能对全球CRP检测市场构成挑战，影响CRP检测结果的准确性、解释和临床实用性。 CRP 水平可能受到各种外部因素的影响，例如吸烟、肥胖和药物。即使没有明显的炎症，这些因素也会导致 CRP 水平升高。医疗保健提供者可能会将升高的 CRP 水平误认为是发炎的表现，而实际上这些升高是由外部影响引起的。当外部因素导致 CRP 水平升高时，医疗保健提供者可能会面临区分 CRP 升高的真正发炎和非发炎原因的挑战。这种复杂性可能会导致准确诊断和管理发炎状况的困难。外部因素可能导致 CRP 检测结果为假阳性或假阴性。例如，由于某些药物的影响，发炎患者的 CRP 水平可能会正常。相反，由于非发炎因素而导致 CRP 水平升高的患者可能会被错误地认为有发炎相关疾病的风险。即使疾病状态没有变化，外部因素也可能导致 CRP 水平随时间波动。这种不一致使得准确监测疾病进展并做出明智的治疗决策变得具有挑战性。

主要市场趋势

  • 1.个人化医疗需求不断增长：个人化医疗需求不断增长是全球C反应蛋白（CRP）检测市场的重要趋势，影响其成长和应用。个人化医疗旨在根据患者的独特特征（包括基因组成、生活方式和生物标记概况）为其量身定制医疗治疗和干预措施。个人化医疗依赖生物标记来指导治疗决策。 CRP 测试是评估发炎的一个有价值的生物标记物，发炎在多种疾病中发挥作用。医疗保健提供者利用 CRP 水平来帮助确定适合个别患者的最合适的治疗策略。 CRP 测试透过评估个人罹患某些疾病（例如心血管疾病）的风险，有助于个人化医疗。 CRP 水平升高可能表示风险增加，促使医疗保健提供者实施针对患者风险状况的预防措施和生活方式干预措施。在个人化医疗中，持续监测疾病进展至关重要。 CRP 测试提供了一种监测发炎程度随时间变化的方法，使医疗保健提供者能够根据 CRP 水平和疾病状态的变化调整治疗计划。个人化医疗涉及监测患者对治疗的反应。 CRP 测试可帮助医疗保健提供者透过追踪发炎程度的变化来评估干预措施的有效性。如果 CRP 水平下降，可能表示对治疗有积极反应。

细分市场洞察

检测类型见解：

2022 年，免疫比浊分析领域主导了 C 反应蛋白检测市场，预计在未来几年将继续扩张。免疫比浊分析具有高度准确度和精密度，使其成为临床应用的理想选择。它们相对容易使用，适合各种环境，包括医院、诊所和诊断实验室。此外，它们具有成本效益，使其成为注重预算的组织的首选。免疫比浊测定透过测量溶液散射的光量来确定分析物的浓度。预计 2023 年至 2030 年该细分市场将经历最高的复合年增长率 (CAGR)。

检测范围洞察：

2022 年，hs-CRP 3 细分市场主导 C 反应蛋白检测市场，预计在未来几年将持续成长。 hs-CRP 3 检测比传统 CRP 检测更灵敏，使其能够检测较低水平的 CRP。这使得它们对于评估心血管疾病的风险特别有价值。这些检测方法被临床医生广泛接受并纳入许多临床指引中。它们也相对具有成本效益，使其成为注重预算的组织的合适选择。

疾病领域洞察：

2022 年，心血管疾病 (CVD) 领域主导 C 反应蛋白检测市场，预计将继续扩张。心血管疾病是全世界死亡的主要原因，CRP 水平升高与心臟病和中风等心血管疾病的风险增加有关。 CRP 检测用于评估高风险族群（例如患有糖尿病、高血压或高胆固醇的人）患 CVD 的风险。它也用于监测 CVD 治疗的有效性，包括他汀类药物和阿斯匹灵。

最终用途产业见解：

2022年，医院领域主导了C反应蛋白检测市场，预计未来几年将持续成长。 COVID-19、冠状动脉疾病 (CVD) 和癌症相关感染等疾病的日益普及导致住院人数增加，从而增加了对 CRP 检测试剂盒的需求。

区域洞察

北美已成为全球 C 反应蛋白检测市场的领导者。随着心血管疾病发病率的不断上升、持续不断的产品推出、市场上成熟的参与者、尖端技术和完善的医疗保健系统，北美继续推动 CRP 检测市场的成长。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球 C 反应蛋白检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依测定类型（免疫比浊测定、ELISA、化学发光免疫测定、其他）
    • 依检测范围（hs-CRP、传统 CRP、cCRP）
    • 依疾病领域（心血管疾病、癌症、类风湿性关节炎、发炎性肠道疾病、子宫内膜异位症、红斑性狼疮等）
    • 依最终用途行业（诊所和医院、实验室、辅助生活医疗设施、家庭护理、其他）
    • 按公司划分 (2022)
    • 按地区
  • 市场地图

第 6 章：北美 C 反应蛋白检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用途行业
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲 C 反应蛋白检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用途行业
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区 C 反应蛋白检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按检测类型
    • 按检测范围
    • 按疾病领域
    • 按最终用途行业
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲 C 反应蛋白检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按检测类型
    • 按检测范围
    • 按疾病领域
    • 按最终用途行业
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲 C 反应蛋白检测市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按检测类型
    • 按检测范围
    • 按疾病领域
    • 按最终用途行业
    • 按国家/地区
  • MEA：国家分析
    • 南非 C 反应蛋白检测
    • 沙乌地阿拉伯 C 反应蛋白检测
    • 阿联酋 C 反应蛋白检测

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：大环境分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Danaher
    • Quest Diagnostics
    • Siemens Healthineers AG
    • Abbott
    • Merck KGaAA
    • Zoetis
    • Ortho Clinical Diagnostics
    • Getein Biotech, Inc.

第 16 章：策略建议

简介目录
Product Code: 17192

The Global C-reactive Protein Testing Market reached a value of USD 1601.01 Million in 2022 and is poised for robust growth during the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 2.16% through 2028 an dis expected to reach USD 1835.28 Million in 2028. C-reactive Protein Testing, a laboratory examination, assesses the level of C-reactive protein in the bloodstream. This particular protein is synthesized by the liver in response to bodily inflammation. It forms an integral part of the body's innate immune reaction to infections, injuries, or other inflammatory stimuli. Typically, CRP testing involves a blood sample, and results are reported as milligrams of CRP per litre of blood (mg/L). Normal CRP levels are generally low, while elevated levels may signify ongoing inflammation or infection. It's important to note that factors like smoking, obesity, and certain medications can also influence CRP levels. CRP testing is commonly utilized as an inflammation marker in various medical contexts. Healthcare professionals frequently order CRP tests to aid in the diagnosis and monitoring of a range of conditions, including infections, autoimmune diseases, cardiovascular diseases, trauma or surgery, and treatment monitoring.

Key Market Drivers

  • 1. Growing Incidence of Inflammatory and Infectious Diseases: The increasing prevalence of inflammatory and infectious diseases significantly contributes to the expansion of the global C-reactive protein (CRP) testing market. These diseases often trigger an immune response, resulting in elevated CRP levels in the bloodstream. As the incidence of these diseases rises, healthcare providers increasingly require dependable diagnostic tools to detect and monitor inflammation. CRP testing offers a convenient and effective means of assessing inflammation levels, facilitating the diagnosis and management of various conditions. Timely detection of inflammation is pivotal for effective disease management and complications prevention. CRP testing allows for early identification of inflammation, enabling healthcare professionals to intervene before the condition worsens. This aligns with the broader trend of focusing on preventive healthcare and early disease detection. Many chronic diseases, such as rheumatoid arthritis, inflammatory bowel disease, and certain autoimmune disorders, involve ongoing inflammation. CRP testing helps clinicians monitor the severity of inflammation and adjust treatment plans accordingly. As the prevalence of these chronic conditions increases, the demand for CRP testing as a monitoring tool also grows. Inflammation is a recognized risk factor for cardiovascular diseases (CVD), including heart attacks and strokes. Elevated CRP levels have been associated with increased CVD risk. Healthcare providers use CRP testing as part of an overall risk assessment for CVD, which can influence treatment decisions and lifestyle recommendations. CRP levels can rise in response to infections, both bacterial and viral. Monitoring CRP levels can aid in tracking the progression of infections, evaluating the effectiveness of antimicrobial therapies, and determining when a patient is recovering. The increasing prevalence of inflammatory and infectious diseases has prompted extensive research into the role of inflammation in various health conditions. This research generates insights into the relationship between CRP levels and disease outcomes, further highlighting the importance of CRP testing in clinical practice.
Market Overview
Forecast Period2024-2028
Market Size 2022USD 1601.01 Million
Market Size 2028USD 1835.28 Million
CAGR 2023-20282.16%
Fastest Growing SegmentImmunoturbidimetric Assays
Largest MarketNorth America
  • 2. Increasing Awareness of Preventive Healthcare: The rising awareness of preventive healthcare significantly impacts the growth of the global C-reactive protein (CRP) testing market. Preventive healthcare focuses on identifying health issues at an early stage, even before symptoms become apparent. CRP testing serves as a valuable tool in this context by detecting low-grade inflammation that might not be clinically evident yet. Early detection of inflammation through CRP testing enables timely intervention and management, potentially preventing the progression of underlying diseases. Preventive healthcare often involves assessing an individual's risk of developing certain diseases. CRP testing can contribute to risk stratification by providing information about a person's inflammation levels. Elevated CRP levels are associated with an increased risk of conditions such as cardiovascular diseases, making CRP testing a valuable component of risk assessment protocols. The awareness of preventive healthcare promotes the idea of personalized health plans tailored to an individual's specific risk factors and health needs. CRP testing adds an objective biomarker to guide these personalized plans, helping healthcare providers design interventions and lifestyle modifications that address inflammation-related risks. Preventive healthcare often emphasizes lifestyle modifications to promote better health outcomes. CRP testing results can serve as a tangible marker that motivates individuals to make healthier choices, such as improving their diet, increasing physical activity, and quitting smoking. The availability of CRP testing supports educational efforts aimed at empowering individuals to take control of their health. Public health initiatives and screening programs are a part of preventive healthcare efforts. CRP testing can be integrated into these programs to identify individuals at risk of inflammatory conditions and related diseases. This proactive approach can lead to early interventions, reducing the burden of chronic diseases on healthcare systems.
  • 3. Increasing Geriatric Population and Associated Chronic Diseases: The rising geriatric population and the associated prevalence of chronic diseases play a significant role in driving the growth of the global C-reactive protein (CRP) testing market. Aging is associated with changes in the immune system, making older adults more susceptible to inflammation. Chronic low-grade inflammation, known as inflammaging, is common in the elderly and contributes to the development of various age-related chronic diseases. CRP testing is a valuable tool to assess and monitor this chronic inflammation, providing insights into disease risk and progression. The geriatric population is more prone to chronic diseases such as cardiovascular diseases, diabetes, osteoarthritis, and certain cancers. CRP testing helps healthcare providers evaluate the inflammatory component of these diseases, aiding in their diagnosis, management, and monitoring. Older adults are at an increased risk of cardiovascular diseases, and inflammation is a key factor in their pathogenesis. CRP testing is used to assess cardiovascular risk and guide treatment decisions, particularly in the elderly population, where preventive measures are crucial. Elderly individuals often have multiple chronic conditions simultaneously. CRP testing provides insights into the overall inflammatory status, helping healthcare providers manage multimorbidity more effectively and make informed treatment choices. Older adults are more susceptible to infections due to age-related changes in the immune system. CRP levels can rise in response to infections, aiding in the assessment and monitoring of infectious diseases, which can have more serious consequences in the elderly. Preventive healthcare in the geriatric population emphasizes early detection and intervention to prevent disease progression and improve quality of life. CRP testing contributes to this approach by detecting inflammation at an early stage, allowing for timely interventions and personalized treatment plans. Geriatric care facilities and long-term care settings often serve individuals with complex health needs. CRP testing is a valuable tool in these settings for monitoring residents' health, identifying potential infections, and managing chronic diseases.

Key Market Challenges

  • 1. Non-Specificity of Elevated CRP: The non-specificity of elevated C-reactive protein (CRP) levels poses a challenge to the global CRP testing market primarily because it can lead to uncertainties in diagnosis and treatment decisions. Elevated CRP levels indicate the presence of inflammation, but they do not provide specific information about the underlying cause of inflammation. This lack of specificity can lead to diagnostic confusion, as healthcare providers may need to conduct additional tests to pinpoint the exact condition causing the elevated CRP. As a result, there might be delays in diagnosing the actual underlying disease. The non-specific nature of CRP elevation can lead to situations where CRP testing is ordered excessively or inappropriately, contributing to unnecessary healthcare costs and resource utilization. Healthcare providers may order CRP tests in cases where inflammation is present but not clinically significant, potentially leading to overdiagnosis and overuse of healthcare services.
  • 2. Varied Reference Ranges: Different laboratories and healthcare facilities may use varying reference ranges

for defining normal, elevated, and high CRP levels. This inconsistency can lead to confusion among healthcare providers and patients when interpreting CRP test results. A value that is considered normal in one setting might be categorized as elevated in another, affecting clinical decision-making. Varied reference ranges can create uncertainty about whether a given CRP level is within a normal range or indicative of inflammation. This ambiguity can lead to challenges in diagnosing inflammatory conditions accurately, potentially delaying appropriate treatment and management. Efforts to establish standardized reference ranges for CRP levels can help ensure consistent interpretation across different settings and laboratories. Professional medical organizations can provide guidelines and recommendations for interpreting CRP test results and defining reference ranges based on clinical evidence and consensus.

  • 3. Influence of External Factors: The influence of external factors on C-reactive protein (CRP) levels can pose challenges to the global CRP testing market, affecting the accuracy, interpretation, and clinical utility of CRP test results. CRP levels can be affected by various external factors, such as smoking, obesity, and medications. These factors can lead to elevated CRP levels even in the absence of significant inflammation. Healthcare providers may misinterpret elevated CRP levels as indicative of inflammation when they are actually driven by external influences. When external factors contribute to elevated CRP levels, healthcare providers may face challenges in distinguishing between true inflammation and non-inflammatory causes of CRP elevation. This complexity can lead to difficulties in accurately diagnosing and managing inflammatory conditions. External factors can lead to false positive or false negative CRP test results. For example, a patient with inflammation might have normal CRP levels due to the influence of certain medications. Conversely, a patient with elevated CRP levels due to non-inflammatory factors might be wrongly considered at risk for inflammation-related conditions. External factors can lead to fluctuations in CRP levels over time, even in the absence of changes in disease status. This inconsistency can make it challenging to monitor disease progression accurately and make informed treatment decisions.

Key Market Trends

  • 1. Rising Demand for Personalized Medicine: The rising demand for personalized medicine is a significant trend in the global C-reactive protein (CRP) testing market, influencing its growth and application. Personalized medicine aims to tailor medical treatment and interventions to individual patients based on their unique characteristics, including genetic makeup, lifestyle, and biomarker profiles. Personalized medicine relies on biomarkers to guide treatment decisions. CRP testing serves as a valuable biomarker for assessing inflammation, which plays a role in various diseases. Healthcare providers use CRP levels to help determine the most appropriate treatment strategies for individual patients. CRP testing contributes to personalized medicine by assessing an individual's risk for certain diseases, such as cardiovascular diseases. Elevated CRP levels can indicate increased risk, prompting healthcare providers to implement preventive measures and lifestyle interventions tailored to the patient's risk profile. In personalized medicine, ongoing monitoring of disease progression is essential. CRP testing provides a means to monitor the level of inflammation over time, enabling healthcare providers to adjust treatment plans based on changes in CRP levels and disease status. Personalized medicine involves monitoring a patient's response to treatment. CRP testing helps healthcare providers gauge the effectiveness of interventions by tracking changes in inflammation levels. If CRP levels decrease, it may indicate a positive response to treatment.

Segmental Insights

Assay Type Insights:

In 2022, the immunoturbidimetric assays segment dominated the C-reactive Protein Testing market and is expected to continue its expansion in the years ahead. Immunoturbidimetric assays are highly accurate and precise, making them ideal for clinical applications. They are relatively easy to use and suitable for various settings, including hospitals, clinics, and diagnostic laboratories. Additionally, they are cost-effective, making them a preferred option for budget-conscious organizations. Immunoturbidimetric assays measure the amount of light scattered by a solution to determine the concentration of an analyte. This segment is projected to experience the highest Compound Annual Growth Rate (CAGR) from 2023 to 2030.

Detection Range Insight:

In 2022, the hs-CRP 3 segment dominated the C-reactive Protein Testing market and is expected to continue its growth in the coming years. hs-CRP 3 assays are more sensitive than conventional CRP assays, enabling them to detect lower levels of CRP. This makes them particularly valuable for assessing the risk of cardiovascular disease. These assays are widely accepted by clinicians and incorporated into many clinical guidelines. They are also relatively cost-effective, making them a suitable choice for budget-conscious organizations.

Disease Area Insight:

In 2022, the cardiovascular diseases (CVD) segment dominated the C-reactive Protein Testing market and is expected to continue its expansion. Cardiovascular diseases are the leading cause of death worldwide, and elevated CRP levels are associated with an increased risk of developing CVD, such as heart attacks and strokes. CRP testing is used to assess the risk of developing CVD in high-risk individuals, such as those with diabetes, high blood pressure, or high cholesterol. It is also employed to monitor the effectiveness of CVD treatment, including statins and aspirin.

End-Use Industry Insights:

In 2022, the hospital segment dominated the C-reactive Protein Testing market and is expected to continue its growth in the coming years. The increasing prevalence of diseases such as COVID-19, coronary artery disease (CVD), and cancer-related infections has led to higher hospital admissions, thereby increasing the demand for CRP test kits.

Regional Insights

North America has established itself as the leader in the global C-reactive Protein Testing Market. With a growing incidence of cardiovascular disease, a consistent stream of product introductions, well-established players in the market, cutting-edge technology, and a well-established healthcare system, North America continues to drive the growth of the CRP testing market.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Abbott
  • Merck KGaAA
  • Zoetis
  • Ortho Clinical Diagnostics
  • Getein Biotech, Inc.

Report Scope:

In this report, the Global C-reactive Protein Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

C-reactive Protein Testing Market, By Assay Type:

  • Immunoturbidimetric Assay
  • ELISA
  • Chemiluminescence Immunoassay
  • Others

C-reactive Protein Testing Market, By Detection Range:

  • hs-CRP
  • Conventional CRP
  • cCRP

C-reactive Protein Testing Market, By Disease Area:

  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Endometriosis
  • Lupus
  • Others

C-reactive Protein Testing Market, By End-User:

  • Hospitals & Clinics
  • Laboratories
  • Assisted Living Healthcare Facilities
  • Homecare
  • Others

Global C-reactive Protein Testing Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global C-reactive Protein Testing Market.

Available Customizations:

  • Global C-reactive Protein Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global C-reactive Protein Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others)
    • 5.2.2. By Detection Range (hs-CRP, Conventional CRP, cCRP)
    • 5.2.3. By Disease Area (Cardiovascular Disease, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others)
    • 5.2.4. By End-Use Industry (Clinics and Hospitals, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America C-reactive Protein Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End-Use Industry
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States C-reactive Protein Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Assay Type
        • 6.3.1.2.2. By Detection Range
        • 6.3.1.2.3. By Disease Area
        • 6.3.1.2.4. By End-Use Industry
    • 6.3.2. Mexico C-reactive Protein Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Assay Type
        • 6.3.2.2.2. By Detection Range
        • 6.3.2.2.3. By Disease Area
        • 6.3.2.2.4. By End-Use Industry
    • 6.3.3. Canada C-reactive Protein Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Assay Type
        • 6.3.3.2.2. By Detection Range
        • 6.3.3.2.3. By Disease Area
        • 6.3.3.2.4. By End-Use Industry

7. Europe C-reactive Protein Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End-Use Industry
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France C-reactive Protein Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Assay Type
        • 7.3.1.2.2. By Detection Range
        • 7.3.1.2.3. By Disease Area
        • 7.3.1.2.4. By End-Use Industry
    • 7.3.2. Germany C-reactive Protein Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Assay Type
        • 7.3.2.2.2. By Detection Range
        • 7.3.2.2.3. By Disease Area
        • 7.3.2.2.4. By End-Use Industry
    • 7.3.3. United Kingdom C-reactive Protein Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Assay Type
        • 7.3.3.2.2. By Detection Range
        • 7.3.3.2.3. By Disease Area
        • 7.3.3.2.4. By End-Use Industry
    • 7.3.4. Italy C-reactive Protein Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Assay Type
        • 7.3.4.2.2. By Detection Range
        • 7.3.4.2.3. By Disease Area
        • 7.3.4.2.4. By End-Use Industry
    • 7.3.5. Spain C-reactive Protein Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Assay Type
        • 7.3.5.2.2. By Detection Range
        • 7.3.5.2.3. By Disease Area
        • 7.3.5.2.4. By End-Use Industry

8. Asia-Pacific C-reactive Protein Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Assay Type
    • 8.2.2. By Detection Range
    • 8.2.3. By Disease Area
    • 8.2.4. By End-Use Industry
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China C-reactive Protein Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Assay Type
        • 8.3.1.2.2. By Detection Range
        • 8.3.1.2.3. By Disease Area
        • 8.3.1.2.4. By End-Use Industry
    • 8.3.2. India C-reactive Protein Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Assay Type
        • 8.3.2.2.2. By Detection Range
        • 8.3.2.2.3. By Disease Area
        • 8.3.2.2.4. By End-Use Industry
    • 8.3.3. South Korea C-reactive Protein Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Assay Type
        • 8.3.3.2.2. By Detection Range
        • 8.3.3.2.3. By Disease Area
        • 8.3.3.2.4. By End-Use Industry
    • 8.3.4. Japan C-reactive Protein Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Assay Type
        • 8.3.4.2.2. By Detection Range
        • 8.3.4.2.3. By Disease Area
        • 8.3.4.2.4. By End-Use Industry
    • 8.3.5. Australia C-reactive Protein Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Assay Type
        • 8.3.5.2.2. By Detection Range
        • 8.3.5.2.3. By Disease Area
        • 8.3.5.2.4. By End-Use Industry

9. South America C-reactive Protein Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Assay Type
    • 9.2.2. By Detection Range
    • 9.2.3. By Disease Area
    • 9.2.4. By End-Use Industry
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil C-reactive Protein Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Assay Type
        • 9.3.1.2.2. By Detection Range
        • 9.3.1.2.3. By Disease Area
        • 9.3.1.2.4. By End-Use Industry
    • 9.3.2. Argentina C-reactive Protein Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Assay Type
        • 9.3.2.2.2. By Detection Range
        • 9.3.2.2.3. By Disease Area
        • 9.3.2.2.4. By End-Use Industry
    • 9.3.3. Colombia C-reactive Protein Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Assay Type
        • 9.3.3.2.2. By Detection Range
        • 9.3.3.2.3. By Disease Area
        • 9.3.3.2.4. By End-Use Industry

10. Middle East and Africa C-reactive Protein Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Assay Type
    • 10.2.2. By Detection Range
    • 10.2.3. By Disease Area
    • 10.2.4. By End-Use Industry
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa C-reactive Protein Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Assay Type
        • 10.3.1.2.2. By Detection Range
        • 10.3.1.2.3. By Disease Area
        • 10.3.1.2.4. By End-Use Industry
    • 10.3.2. Saudi Arabia C-reactive Protein Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Assay Type
        • 10.3.2.2.2. By Detection Range
        • 10.3.2.2.3. By Disease Area
        • 10.3.2.2.4. By End-Use Industry
    • 10.3.3. UAE C-reactive Protein Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value &
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Assay Type
        • 10.3.3.2.2. By Detection Range
        • 10.3.3.2.3. By Disease Area
        • 10.3.3.2.4. By End-Use Industry

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Thermo Fisher Scientific, Inc.
    • 15.6.2. F. Hoffmann-La Roche Ltd.
    • 15.6.3. Danaher
    • 15.6.4. Quest Diagnostics
    • 15.6.5. Siemens Healthineers AG
    • 15.6.6. Abbott
    • 15.6.7. Merck KGaAA
    • 15.6.8. Zoetis
    • 15.6.9. Ortho Clinical Diagnostics
    • 15.6.10. Getein Biotech, Inc.

16. Strategic Recommendations